PEPSVN / GUIDES
Semaglutide, tirzepatide & retatrutide
Compare the research pathways, body-composition outcomes and tolerability topics covered in this guide. The detailed sections explain the context behind each comparison.
At a glance
- Receptors and research comparisons
- Side effects and lean mass
- Related research and references
Choose a topic below to read more.
Overview & background
Semaglutide, Tirzepatide, and Retatrutide are often grouped together, but they are not the same tool. They affect different gut-hormone pathways, which changes appetite, insulin response, liver glucose output, energy expenditure, fat loss, and side-effect patterns.
This guide explains what the pancreas does, what the liver does, why insulin sensitivity matters, why muscle loss happens during rapid weight loss, and why compounds like MOTS-c, AOD9604, 5-Amino-1MQ, and SLU-PP-332 are discussed as complementary research compounds.
GLP-1 mainly reduces appetite and improves glucose handling. GIP adds another incretin signal that may affect insulin response and nutrient partitioning. Glucagon can increase liver glucose release but also raises energy expenditure and fat oxidation.
Semaglutide vs Tirzepatide vs Retatrutide
People often ask for exact percentages for GLP-1, GIP, and glucagon activity. That is not how these drugs should be compared. Receptor pharmacology depends on binding affinity, potency, tissue expression, dose, exposure time, and downstream signaling. So the chart below uses practical relative pathway emphasis, not exact biological percentages.
| Compound | Receptor profile | Relative pathway emphasis | What that means in plain English |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Mostly appetite suppression, slower gastric emptying, increased glucose-dependent insulin secretion, and reduced inappropriate glucagon signaling. | |
| Tirzepatide | Dual GIP + GLP-1 receptor agonist | Adds GIP signaling to GLP-1, which may support stronger glucose control, insulin response after meals, and improved body-composition outcomes. | |
| Retatrutide | Triple GIP + GLP-1 + glucagon receptor agonist | Combines appetite and glucose effects with a glucagon signal that is researched for increased energy expenditure, fat oxidation, and liver-metabolism effects. |
Weight loss, fat loss, lean mass loss, and tolerability
Trial results are not perfectly comparable because study length, population, dose escalation, adherence, and measurement methods differ. Still, they show the general pattern: more receptor pathways tend to produce more weight loss, but often with more gastrointestinal side-effect management needed.
| Compound | Major research signal | Approx. weight-loss signal | Fat vs lean mass | Common side effects |
|---|---|---|---|---|
| Semaglutide | GLP-1 focused appetite and glucose pathway | Often discussed around ~15% average weight loss in obesity trials. | Fat mass decreases substantially, but lean mass also falls. Some analyses estimate a relatively large lean-mass fraction of total weight lost. | Nausea, constipation, diarrhea, reflux, reduced appetite, vomiting, fatigue, dehydration risk if intake drops too low. |
| Tirzepatide | Dual incretin pathway: GLP-1 + GIP | Often discussed around ~20%+ average weight loss in higher-dose obesity trials. | Body-composition analyses suggest most loss is fat mass, with lean mass loss commonly around one-quarter of total weight lost. | Similar GI pattern: nausea, diarrhea, constipation, vomiting, reflux, appetite suppression. Side effects often depend on dose escalation speed. |
| Retatrutide | Triple agonist: GLP-1 + GIP + glucagon | Phase 2 showed very large weight-loss signals; newer Phase 3 updates report even stronger average loss over longer study periods. | Still being studied. Because total weight loss is larger, lean-mass preservation becomes especially important even if the percentage split is similar. | GI effects remain central: nausea, vomiting, diarrhea, constipation, appetite suppression, and dose-related tolerability concerns. |
What the pancreas and liver are doing
The most useful way to understand these compounds is to look at the organ-level signals: brain, stomach, pancreas, liver, muscle, and fat tissue.
Insulin release
GLP-1 and GIP both help the pancreas release insulin in a glucose-dependent way. That means the signal is stronger when glucose is elevated and less active when glucose is low.
This is why incretin compounds are researched for glucose control as well as weight management.
Glucagon control
GLP-1 tends to suppress inappropriate glucagon release from alpha cells. That matters because glucagon tells the liver to release glucose.
In type 2 diabetes research, reducing inappropriate liver glucose output is a big part of improving fasting glucose.
Glucose output
The liver stores glucose as glycogen and can release glucose when the body needs it. Glucagon increases that release.
Retatrutide is interesting because glucagon can increase energy expenditure while GLP-1 and GIP help balance glucose and appetite signals.
Insulin sensitivity
Better insulin sensitivity means muscle and other tissues respond to insulin more effectively, so glucose can move out of the blood and into cells more efficiently.
Weight loss itself improves insulin sensitivity, but compounds like MOTS-c are researched specifically for muscle glucose uptake and AMPK signaling.
Energy storage vs release
Fat tissue is not just passive storage. It responds to insulin, inflammation, calorie balance, and hormone signals.
Compounds like AOD9604 and 5-Amino-1MQ are discussed because they target fat metabolism from different angles than GLP-1 appetite suppression.
Appetite and fullness
GLP-1 pathways reduce appetite, increase fullness, and slow gastric emptying. That is useful, but it can also reduce protein intake if researchers are not careful.
Less food is not automatically better if lean mass, hydration, minerals, or protein intake collapse.
Why GLP-1 side effects happen
Most common side effects are tied to the same mechanisms that make these compounds effective: slower gastric emptying, stronger fullness signals, lower food intake, and altered gut-brain signaling.
Nausea and vomiting
Slower stomach emptying and stronger satiety signaling can make food sit longer and make meals feel heavier. Fast dose escalation often makes this worse.
Constipation or diarrhea
Gut motility changes, lower food volume, lower fluid intake, and lower fiber intake can all shift bowel patterns.
Low intake problems
Appetite suppression can accidentally become protein suppression, hydration suppression, and micronutrient suppression. That is where fatigue and lean-mass loss become more likely.
Why muscle loss happens during GLP-1 weight loss
GLP-1 compounds do not simply “burn muscle.” Lean mass loss usually happens because rapid weight loss changes the whole environment: less food, less protein, less training stimulus, less mechanical loading, and lower total energy availability.
Calorie deficit
When energy intake drops sharply, the body uses stored energy. Most comes from fat, but some can come from lean tissue, especially if protein and training are poor.
Low protein intake
Appetite suppression often makes people eat less of everything. If protein falls too low, muscle protein synthesis has fewer building blocks.
No resistance training
Muscle is expensive tissue. Without mechanical tension from lifting or resistance work, the body has less reason to keep it during a large deficit.
Read the related PepsVN guides
These pages support the topics above and help compare individual compounds by mechanism.
Retatrutide Guide
GLP-1, GIP, and glucagon pathway research overview.
Dual agonistTirzepatide Guide
GLP-1 and GIP research, mixing examples, and mechanism overview.
MitochondrialMOTS-c Guide
Mitochondrial peptide research and insulin-sensitivity pathway discussion.
Fat metabolismAOD9604 Guide
Lipolysis and fat-metabolism research overview.
NNMT5-Amino-1MQ Guide
NNMT inhibition and metabolic-efficiency research.
Need help comparing GLP-1 research compounds?
Message PepsVN for help understanding Retatrutide, Tirzepatide, MOTS-c, AOD9604, 5-Amino-1MQ, reconstitution math, and batch documentation.
This page is for educational and research-use information only. It is not medical advice, legal advice, dosing guidance, treatment guidance, injection instruction, or a recommendation for human or animal use. Retatrutide is investigational and not approved for public medical use. Peptides and related compounds may be regulated differently depending on jurisdiction. Readers are responsible for understanding and complying with applicable laws and regulations.